Navigation Links
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
Date:12/1/2011

nts an effective treatment for most ER+ MBC patients, however acquired drug resistance to aromatase inhibitors leads to disease progression requiring less effective, more toxic chemotherapies.(1)  Delaying resistance and disease progression represents a significant unmet need that could prolong survival while decreasing health care costs associated with chemotherapy and hospitalization.

Hodgkin's Lymphoma
Hodgkin's lymphoma (HL) is a cancer of lymph tissue found in the lymph nodes, spleen, liver, bone marrow, and other sites.  It is most common among people ages 15 - 35 and 50 - 70.  Although the cause is not known, past infection with the Epstein-Barr virus (EBV) is thought to contribute to some cases and patients with HIV infection are more at risk than the general population.  It is estimated that 8,830 people in the US will be diagnosed with and 1,300 will die of the disease in 2011, with the prognosis of patients with relapsed HL being particularly poor.  HDACi have shown promise in treating this disease.  Preclinical studies have identified at least three complementary mechanisms to explain how HDACi may be effective in the treatment of HL (Buglio, Blood 2008): induction of apoptosis, regulation of cytokines and chemokines and alterations of cancer/testis antigens (Jona et al., Exp Hematol. 2011).

About Entinostat
Syndax's lead product entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. Entinostat is differentiated from other members of the class through its unique selectivity profile, pharmacokinetic properties and safety profile. Entinostat has been studied in more than 600 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies.

Breast cancer anim
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
2. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Biogen-Idecs BG-12 Shines At the Top of the Charts in the Treatment of Relapsing-Remitting Multiple Sclerosis
6. Neurology Devices Market to 2017 - High Potential for Usage of Neurostimulation Devices in Multiple Neurological Disorders to Drive Market Growth
7. Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
8. DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Calipers LabChip® Dx Platform
9. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
10. S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis
11. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... MAHWAH, N.J. , July 30, 2014 Stryker brand ... playing this week at the 3M Championship Champions Tour event near ... Twin Cities, in Blaine . Stryker is the ... Tour. Starting Friday, August 1 st through ... the Stryker Mobility Zone; an on-site joint health destination located in ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
(Date:7/30/2014)... SANTA CLARA, Calif. , July 30, 2014 /PRNewswire/ ... innovation economy, released a study today that ... venture-backed biopharma and medical device companies.  According to the ... healthcare saw the biggest potential returns since SVB started ... the year of the IPO.  Built on solid healthcare ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... 2011 Hypoxic (oxygen-deprived) tumor cells usually resist radiation ... cancer. Researcher Xin Chen, Ph.D. believes that ... with malignant solid tumors in areas such as the ... an assistant professor in the Department Radiation Oncology at ...
... July 26, 2011 SCOLR Pharma, Inc. (OTC: SCLR) today ... ended June 30, 2011 and also provided updates on a ... the Company issued an aggregate of $1.2 million principal amount ... "Debentures") in a private offering of Debentures. The Company intends ...
Cached Medicine Technology:Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation 2Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation 3SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 2SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 3SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 4SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 5SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results 6
(Date:7/30/2014)... Mozes HealthDay Reporter WEDNESDAY, ... help their preschooler shed excess pounds may want to team ... parents joined them in a supervised behavioral modification program gained ... traditional child-only program (an average difference of about four pounds ... 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... 30, 2014 SF Cable, distributor of ... lowest prices on the internet with guaranteed customer satisfaction ... lengths and two colors. These lightning cords are MFI ... The high quality SF Cable Lightning to USB ... signal delivering faster charging and syncing. Compatible with the ...
(Date:7/30/2014)... 30, 2014 Imprivata ® ... management and secure communications solutions for the healthcare ... is the most widely selected single sign-on (SSO) ... Horizon electronic medical records (EMR) systems with a ... 11 percent in the last 12 months), according ...
(Date:7/30/2014)... (HealthDay News) -- Some obese people have a genetic ... in their brains when they see food, researchers report. ... triggers feelings of pleasure and gratification at the sight ... designed to prevent overeating, the scientists suggested. More ... typically caused by a combination of overeating, a ...
(Date:7/30/2014)... A new network of 25 regional stroke centers and ... StrokeNet) is working to change the way stroke ... of the last two decades, stroke remains a major ... disability for 795,000 Americans. The numbers are expected to ... , To accelerate the pace of progress, NIH StrokeNet ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... by a US biotechnology company could block the spread of ... human trial. // ,Human Immunodeficiency Virus (HIV) steadily ... fight off infections such as pneumonia, diarrhea, tumours and other ... die within three years of the first signs of the ...
... not to marry till he passes his Class 10 board exam, ... in the examination yet again! // ,Also known as Sheojiram, ... from here, has been taking the test for the last 37 ... vowed to marry only after getting through his secondary examinations. But ...
... while the chances of surviving a heart attack has improved ... ,The Canadian Institute for Health Information in its ... people suffering a new heart attack fell to 11.1 per ... in the case of strokes, 18.8 per cent of stroke ...
... Organisation (WHO) reaffirmed an additional case of the H5N1 avian ... from Tasikmalaya District, West Java Province who died on May ... in Indonesia have been fatal. The virus has taken a ... WHO report. Aproximately, 200 million birds too have perished.. ...
... Blair had lauded the initiation of a high profile, high-tech ... hospitals with the Britain’s 50 million patients//. Today however ... ,According to the first set grandiose plans, by 2005, ... immediately to surgeries. This would be followed by prescriptions that ...
... the intake of calcium and vitamin D supplements is apparently ... according to new results //from the Women's Health Initiative study. ... in decreasing the cancer risk. ,'We can't yet ... D individuals should take each day as supplements,' said Dr. ...
Cached Medicine News:Health News:New Revolutionary Drug Could Stop the Spread of HIV 2Health News:Survival Rates of Heart Attack Improving 2Health News:NHS Billions Spent on High Cost Computer Scheme 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: